Eileen Martin1, Raul Gonzalez2, Jasmin Vassileva3, Antoine Bechara4. 1. Department of Psychiatry, Rush University Medical Center. 2. Department of Psychology, Florida International University. 3. Department of Psychiatry, Virginia Commonwealth University. 4. Department of Psychology, University of Southern California.
Abstract
OBJECTIVE: Substance dependent individuals (SDIs) typically overvalue immediate and undervalue (discount) delayed rewards, and level of discounting significantly predicts posttreatment relapse and other behavioral outcomes. Delay discounting has potential significance for studies of HIV prevention and adherence to antiretroviral therapy; but effects of HIV infection on delay discounting rates among SDIs are not well understood, although discounting rates are higher among individuals infected with hepatitis C virus (HCV). In this study, we investigated potential additive or interactive effects of HIV and HCV infection on delay discounting performance among a group of 239 SDIs with verified HIV and HCV serostatus. METHOD: All participants were verified abstinent from drugs and alcohol at testing. All participants completed measures of substance abuse characteristics and comorbid disorders, and the Monetary Choice Questionnaire, a well-known measure used to derive k coefficients, which index discounting rates. RESULTS: Groups were comparable on demographic, substance use, and comorbid characteristics. Compared with uninfected controls, discounting rates were significantly higher among individuals seropositive for HCV but not HIV. Additionally, no significant group differences in discounting rates were observed among HCV+ participants with or without coinfection with HIV. Group differences could not be attributed to aging or nonspecific effects of drug addiction. Additionally, increased discounting rates were associated with riskier injection practices. CONCLUSIONS: Potential mechanisms contributing to this discrepancy in discounting rates between HIV+ and HCV+ SDIs, including decision making, are discussed and await further study. (c) 2015 APA, all rights reserved).
OBJECTIVE: Substance dependent individuals (SDIs) typically overvalue immediate and undervalue (discount) delayed rewards, and level of discounting significantly predicts posttreatment relapse and other behavioral outcomes. Delay discounting has potential significance for studies of HIV prevention and adherence to antiretroviral therapy; but effects of HIV infection on delay discounting rates among SDIs are not well understood, although discounting rates are higher among individuals infected with hepatitis C virus (HCV). In this study, we investigated potential additive or interactive effects of HIV and HCV infection on delay discounting performance among a group of 239 SDIs with verified HIV and HCV serostatus. METHOD: All participants were verified abstinent from drugs and alcohol at testing. All participants completed measures of substance abuse characteristics and comorbid disorders, and the Monetary Choice Questionnaire, a well-known measure used to derive k coefficients, which index discounting rates. RESULTS: Groups were comparable on demographic, substance use, and comorbid characteristics. Compared with uninfected controls, discounting rates were significantly higher among individuals seropositive for HCV but not HIV. Additionally, no significant group differences in discounting rates were observed among HCV+ participants with or without coinfection with HIV. Group differences could not be attributed to aging or nonspecific effects of drug addiction. Additionally, increased discounting rates were associated with riskier injection practices. CONCLUSIONS: Potential mechanisms contributing to this discrepancy in discounting rates between HIV+ and HCV+ SDIs, including decision making, are discussed and await further study. (c) 2015 APA, all rights reserved).
Authors: Yannis Paloyelis; Philip Asherson; Mitul A Mehta; Stephen V Faraone; Jonna Kuntsi Journal: Neuropsychopharmacology Date: 2010-08-25 Impact factor: 7.853
Authors: Raul Gonzalez; Jasmin Vassileva; Antoine Bechara; Silvana Grbesic; Lisa Sworowski; Richard M Novak; Gerald Nunnally; Eileen M Martin Journal: J Int Neuropsychol Soc Date: 2005-03 Impact factor: 2.892
Authors: Daniel M Forton; Joanna M Allsop; I Jane Cox; Gavin Hamilton; Keith Wesnes; Howard C Thomas; Simon D Taylor-Robinson Journal: AIDS Date: 2005-10 Impact factor: 4.177
Authors: Eileen M Martin; David L Pitrak; William Weddington; Niles A Rains; Gerald Nunnally; Heather Nixon; Silvana Grbesic; Jasmin Vassileva; Antoine Bechara Journal: J Int Neuropsychol Soc Date: 2004-11 Impact factor: 2.892
Authors: Marilyn Huckans; Adriana Seelye; Jonathan Woodhouse; Tiffany Parcel; Lisa Mull; Daniel Schwartz; Alex Mitchell; David Lahna; Amy Johnson; Jennifer Loftis; Steven Paul Woods; Suzanne H Mitchell; William Hoffman Journal: J Clin Exp Neuropsychol Date: 2010-08-06 Impact factor: 2.475
Authors: Holly McCready; Milky Kohno; Michael Kolessar; Laura Dennis; Daniel Kriz; Hannah Luber; Renee Anderson; Michael Chang; Anna Sasaki; Kenneth Flora; Arthur Vandenbark; Suzanne H Mitchell; Jennifer M Loftis; William F Hoffman; Marilyn Huckans Journal: J Neurovirol Date: 2018-10-08 Impact factor: 2.643
Authors: Cory Czuczman; Morgan Thompson; E Paul Wileyto; Robert Schnoll; David Metzger; Frank Leone; Karam Mounzer; Robert Gross; Rebecca L Ashare Journal: Psychopharmacology (Berl) Date: 2020-11-12 Impact factor: 4.530